David A. Gudis, MD

Scott H. Troob M.D is a double-boarded Head and Neck Oncologist & Microvascular and Facial Plastic Surgeon nationally recognized for providing integrated oncologic and reconstructive care. He currently serves as the Division Chief of Facial Plastic and Reconstructive Surgery in the Department of Otolaryngology – Head and Neck Surgery. During his time at Columbia, he developed the Head and Neck Free Tissue Transfer and Facial Reanimation programs and has earned a reputation for technical excellence and compassionate patient care. He specializes in the treatment of benign conditions of the head and neck as well as the medical and surgical treatment of cancers of the skin, oral cavity, oropharynx, larynx, hypopharynx, sinonasal tract, salivary glands, and skull base. Additionally, Dr. Troob employs state-of-the-art tissue repair and microsurgical techniques to perform reconstructive surgery for patients following head and neck cancer treatment, facial trauma, and facial paralysis. Dr. Troob is a proud graduate of Columbia (CC ’04) where he received his undergraduate BA in Biology and served as the Captain of the Men’s Swimming and Diving Team. He then attended Jefferson Medical College where he graduated summa cum laude and was inducted into the Alpha Omega Alpha Honor Medical Society. He went on to complete his Otolaryngology – Head and Neck Surgery Residency in 2014 at NYU, where he was selected for the Gold Humanism Society in recognition of his excellence in humanistic patient care, leadership, compassion, and dedication to service. Following residency, he left New York for Oregon Health and Science University (OHSU), where he completed a fellowship in Advanced Head and Neck Oncology, Robotic, & Skull Base Surgery in 2015. He remained at OHSU to complete a second fellowship in Microvascular and Facial Plastic Surgery in 2016. Beyond his interest in oncology and reconstruction, Dr. Troob treats a variety of disorders of the salivary glands, focusing on minimally invasive procedures (sialoendoscopy) which allow for treatment of strictures and stones without external incisions.

Dr. Ana H. Kim is board certified in Otolaryngology and Neurotology, specializing in ear diseases such as hearing loss, cochlear implants, facial nerve disorders, chronic ear diseases, and skull base tumors. She focuses on inner ear disorders and potential therapies. Dr. Kim graduated from Cornell University and Albert Einstein College of Medicine. She completed her Otolaryngology residency at the New York Eye and Ear Infirmary, and Neurotology fellowship at the University of Michigan. She is a member of numerous professional societies and also serves on the New York State Hearing Aid Advisory Board. She has authored numerous publications and has presented nationally and internationally.

One of the nation's leading experts in hearing loss, Lawrence Lustig, MD, was appointed chair of the Department of Otolaryngology—Head and Neck Surgery at the Columbia University College of Physicians and Surgeons and otolaryngologist-in-chief at NewYork-Presbyterian Hospital/Columbia University Medical Center, effective July 1, 2014. “We are very pleased to welcome Larry Lustig to our faculty,” said Lee Goldman, MD, dean of the faculties of health sciences and medicine, Columbia University Medical Center. “His experience and success leading major research and clinical programs will help us continue to grow our Department of Otolaryngology/Head and Neck Surgery’s basic, clinical, and translational research programs and our clinical enterprise, including even stronger collaboration with faculty across our departments.” “Dr. Lustig’s extensive background in research and clinical care for hearing loss and related disorders will be pivotal to our continued provision of innovative, outstanding and patient-centered care, said Steven J. Corwin, MD, chief executive officer of NewYork-Presbyterian Hospital. “His expertise adds significantly to the depth and breadth of our ENT program, which addresses a range of health issues including hearing loss, benign and cancerous tumors, nasal and sinus disorders, voice and swallowing issues.” Dr. Lustig treats the full spectrum of ear disorders in adults and children, as well as skull base disease. His specialties include skull base surgery, cochlear implants, the genetics of hearing loss, cochlear gene therapy, balance disorders, and hair cell physiology. He has led several NIH-funded research projects examining the underlying causes of hearing loss, including a recently completed a two-year $550,000 grant to explore cochlear gene therapy as a potential approach to treating children born with genetic forms of hearing loss. This work stems from an initial study in which he and colleagues demonstrated that the inner hair cell glutamate-transporter VGLUT3 is integral to the development of hearing, while a mutation of the transporter causes early profound hearing loss. In follow-up studies, they demonstrated that virally mediated gene therapy can successfully restore the hearing phenotype in a mouse model of genetic deafness. Based on this work, they are currently exploring additional models of genetic deafness to see if these results can be duplicated. NIH has awarded a five-year grant to explore the use of virally mediated gene therapy to regenerate spiral (cochlear) ganglia—nerve cells that transport sound from the cochlea to the brain—to enable the sense of hearing. Dr. Lustig’s interdisciplinary research includes collaboration with an orthopedic surgery researcher at UCSF to study cochlear bone development. Using animal models and molecular techniques applied to bone growth and development, they are looking at how the material properties of bone enclosing the inner ear contribute to hearing. They anticipate that their findings may help further understanding of how metabolic abnormalities cause certain types of hearing loss, including otosclerosis, Padget’s disease, and other conditions that cause defective bone development. Additional collaboration has included work with a pharmacologist at UCSF, where Dr. Lustig studied the mechanism of hearing loss caused by platinum-based chemotherapies. Dr. Lustig has published more than 125 articles in peer-reviewed journals, as well as book chapters. He co-edited a textbook, “Clinical Neurotology: Diagnosing and Managing Disorders of Hearing, Balance and the Facial Nerve.” In 2004, Dr. Lustig joined UCSF, where he has served as chief of the Division of Otology and Neurotology at both UCSF and San Francisco General Hospital, director of the Douglas Grant Cochlear Implant Center, clinical chief of the otolaryngology service on the Parnassus campus, and co-director of the Center for Balance and Falls. Before joining UCSF, Dr. Lustig served on the faculty at Johns Hopkins University, where he was a member of the Johns Hopkins Listening Center and cochlear implant team. He also completed a fellowship in otology, neurotology, and skull base surgery at Hopkins. Dr. Lustig is a member of numerous professional organizations, including the American Otologic Society, the American Auditory Society, the Association for Research in Otolaryngology, the American Neurotology Society, and the North American Skull Base Society. He earned his bachelor’s degree in microbiology at the University of California, Berkeley, and his medical degree at UCSF, where he also completed a residency in otolaryngology/head and neck surgery.